Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...

Merck , known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the ...

Expert Rev Vaccines. 2009;8(8):1051-1061. Simply defined as an extension of the benefit of protection from immunization in those immunized to those unimmunized in a community, herd effect was key ...

SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity of their 21-valent pneumococcal conjugate ... showed that the vaccine had ...

Jan 18 (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los ...

Infants in the vaccinated group received DTaP; the 13-valent pneumococcal conjugate vaccine; and vaccines for HBV, polio and Haemophilus influenzae type b. The researchers monitored the infants ...

Covid vaccines saved lives. Lots of them. Research by the World Health Organization (WHO) now puts the number at 475,000 in the UK with many more kept out of hospital or off a ventilator.